Table 1.
Baseline parameters
| Vaping w/o nicotine | Vaping with nicotine | Sham-vaping | p | |
|---|---|---|---|---|
| Hemodynamic parameters | ||||
| Heart rate (b.p.m)* | 60 ± 2 | 59 ± 2 | 60 ± 2 | >0.7 |
| Humeral systolic blood pressure (mm Hg)* | 110 ± 2 | 109 ± 1 | 110 ± 2 | >0.8 |
| Humeral diastolic blood pressure (mm Hg)* | 68 ± 2 | 68 ± 1 | 68 ± 1 | >0.9 |
| Arterial stiffness indices | ||||
| Aortic sytolic blood pressure (mm Hg)* | 95 ± 2 | 94 ± 1 | 94 ± 2 | >0.8 |
| Aortic diastolic blood pressure (mm Hg)* | 69 ± 1 | 69 ± 1 | 68 ± 1 | >0.6 |
| Aortic pulse pressure (mm Hg)* | 26 ± 1 | 26 ± 1 | 26 ± 1 | >0.9 |
| AIx75 (%)* | −4,5 ± 1.9 | −3.5 ± 1.5 | −3,4 ± 2.1 | >0.6 |
| Carotid–femoral PWV (m/s)* | 4.9 ± 0.1 | 4.9 ± 0.1 | 5 ± 0.1 | >0.6 |
| SEVR* | 184 ± 8 | 193 ± 7 | 184 ± 8 | >0.3 |
| Oxidative stress biomarkers | ||||
| MPO antigen (ng.mL−1)† | 11.9 [3.6–165.5] | 12.2 [4.2–81.1] | 13.6 [7.9–26] | >0.3 |
| P-B-3-Cl-Tyr/Tyr ratio (10−6)† | 59.8 [49–67.5] | 55.7 [47.8–64.1] | 60.3 [48.2–71.9] | >0.8 |
| Hcit/Lys ratio (10−6)† | 218 [192.8–277.4] | 230.1 [195.5–316.6] | 222.3 [203–267] | >0.8 |
w/o, without; AIx75, Augmentation index corrected for heart rate; SEVR, subendocardial viability ratio; MPO, Myeloperoxydase; P-B-3-Cl-Tyr/Tyr, Protein-Bound-3-Chloro-thyrosine/Tyrosine ratio; Hcit/Lys: Homocitrulline/Lysine ratio; humeral systolic and diastolic blood pressure were assessed using auscultatory sphygmomanometer.
*Mean ± SEM.
†Median [interquantile range].